248 related articles for article (PubMed ID: 32780516)
1. Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study.
Chan SL; Yip TC; Wong VW; Tse YK; Yuen BW; Luk HW; Lui RN; Chan HL; Mok TS; Wong GL
Cancer Med; 2020 Oct; 9(19):7052-7061. PubMed ID: 32780516
[TBL] [Abstract][Full Text] [Related]
2. Hepatic immune-mediatedadverseeffects of immune checkpoint inhibitors: analysis of real-life experience.
da Silva JA; Falcão D; Cardoso C; Pires AL; Araújo A; Castro-Poças F
Ann Hepatol; 2021 Dec; 26():100561. PubMed ID: 34653687
[TBL] [Abstract][Full Text] [Related]
3. A descriptive analysis of aspartate and alanine aminotransferase rise and fall following acetaminophen overdose.
Curtis RM; Sivilotti ML
Clin Toxicol (Phila); 2015 Nov; 53(9):849-55. PubMed ID: 26294195
[TBL] [Abstract][Full Text] [Related]
4. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
[TBL] [Abstract][Full Text] [Related]
5. Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors.
Miller ED; Abu-Sbeih H; Styskel B; Nogueras Gonzalez GM; Blechacz B; Naing A; Chalasani N
Am J Gastroenterol; 2020 Feb; 115(2):251-261. PubMed ID: 31789632
[TBL] [Abstract][Full Text] [Related]
6. Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19.
Yip TC; Lui GC; Wong VW; Chow VC; Ho TH; Li TC; Tse YK; Hui DS; Chan HL; Wong GL
Gut; 2021 Apr; 70(4):733-742. PubMed ID: 32641471
[TBL] [Abstract][Full Text] [Related]
7. Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies.
Mizuno K; Ito T; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Kawashima H; Inukai Y; Toyoda H; Yokota K; Hase T; Maeda O; Kiyoi H; Nagino M; Hibi H; Kodera Y; Fujimoto Y; Sone M; Gotoh M; Ando Y; Akiyama M; Hasegawa Y; Fujishiro M
J Gastroenterol; 2020 Jun; 55(6):653-661. PubMed ID: 32124082
[TBL] [Abstract][Full Text] [Related]
8. Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis.
Tian JC; Liu H; Yan LJ; Ding ZN; Han CL; Tian BW; Tan SY; Dong ZR; Wang DX; Xue JS; Mao XC; Yan YC; Li T
Clin Exp Med; 2023 Oct; 23(6):2115-2129. PubMed ID: 36385419
[TBL] [Abstract][Full Text] [Related]
9. Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: A systematic review and meta-analysis.
Balibegloo M; Nejadghaderi SA; Sadeghalvad M; Soleymanitabar A; Salehi Nezamabadi S; Saghazadeh A; Rezaei N
Int Immunopharmacol; 2021 Jul; 96():107796. PubMed ID: 34162158
[TBL] [Abstract][Full Text] [Related]
10. [Immune-related Adverse Events Induced by ICIs in Advanced NSCLC:
A Meta-analysis and Systematic Review].
Qin Q; Wang J; Wang H
Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):772-791. PubMed ID: 32752580
[TBL] [Abstract][Full Text] [Related]
11. Adverse Events Associated with Immune Checkpoint Inhibitors: Overview of Systematic Reviews.
Kanji S; Morin S; Agtarap K; Purkayastha D; Thabet P; Bosse D; Wang X; Lunny C; Hutton B
Drugs; 2022 May; 82(7):793-809. PubMed ID: 35416592
[TBL] [Abstract][Full Text] [Related]
12. Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Yamamoto T; Ito T; Hase T; Ishigami M; Mizuno K; Yamamoto K; Imai N; Ishizu Y; Honda T; Shibata H; Hatta T; Yogo N; Yasuda S; Toyoda H; Abe T; Kawashima H; Hashimoto N; Fujishiro M
Cancer Invest; 2022 Feb; 40(2):189-198. PubMed ID: 34658277
[TBL] [Abstract][Full Text] [Related]
13. Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis.
Genovese MC; Kremer JM; van Vollenhoven RF; Alten R; Scali JJ; Kelman A; Dimonaco S; Brockwell L
Arthritis Rheumatol; 2017 Sep; 69(9):1751-1761. PubMed ID: 28597609
[TBL] [Abstract][Full Text] [Related]
14. Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome.
Colomba E; Marret G; Baciarello G; Lavaud P; Massard C; Loriot Y; Albiges L; Carton E; Alexandre J; Huillard O; Culine S; Fizazi K
Eur J Cancer; 2020 Apr; 129():117-122. PubMed ID: 32151941
[TBL] [Abstract][Full Text] [Related]
15. Hepatotoxicity Associated with Immune Checkpoint Inhibitors in Clinical Practice: A Study Leveraging Data from the US Food and Drug Administration's Adverse Event Reporting System.
Wang H; Yang H; Zhou X; Zhang X
Clin Ther; 2023 Feb; 45(2):151-159. PubMed ID: 36682994
[TBL] [Abstract][Full Text] [Related]
16. Clinical features of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in patients with cancers.
Yamamoto A; Yano Y; Ueda Y; Yasutomi E; Hatazawa Y; Hayashi H; Yoshida R; Asaji N; Shiomi Y; Tobimatsu K; Sakai A; Kodama Y
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1747-1756. PubMed ID: 33222015
[TBL] [Abstract][Full Text] [Related]
17. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis.
Li M; Wong D; Vogel AS; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Hepatology; 2022 Mar; 75(3):531-540. PubMed ID: 34709662
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Pan J; Liu Y; Guo X; Bai Z; Levi Sandri GB; Méndez-Sánchez N; Qi X
Expert Opin Drug Saf; 2022 Oct; 21(10):1275-1287. PubMed ID: 36214583
[TBL] [Abstract][Full Text] [Related]
19. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
Kwo PY; Cohen SM; Lim JK
Am J Gastroenterol; 2017 Jan; 112(1):18-35. PubMed ID: 27995906
[TBL] [Abstract][Full Text] [Related]
20. The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials.
Fujiwara Y; Horita N; Namkoong H; Galsky MD
Eur J Cancer; 2021 Jun; 150():168-178. PubMed ID: 33906099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
